BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — FY2026 Earnings Presentation
16 slides from BTC Health Ltd Registered's earnings presentation, Aug 20, 2026
Slide 1: Investor Presentation – FY26 Results
For personal use only Improving patients’ lives through global BTC Health Limited (ASX:BTC) Investor Presentation – FY26 Results medical innovation August 2026
Slide 2: Disclaimer
Disclaimer Summary information This Presentation contains summary information about BTC health, and its activities current as at 20 August 2026. The information in the presentation is of a general For personal use only nature and does not purport to be complete or comprise all information which a sh
Slide 3: Group structure & Background
Group structure & Background For personal use only BTC Health Ltd 100% 100% 100% BTC Speciality BTC Cardio PL BTC Pharma PL Health PL Post-Operative Specialised Neuro-Spinal Cardio-thoracic Critical Care Pain Pharmaceuticals BTC Health Ltd (“the Company”) is a registered Pooled Development Fund (PDF
Slide 4: Core business strengthened in FY26
Strategy Core business strengthened in FY26 For personal use only • Reset cost base Group operating costs reduced 2% to $4.23m, or 41.1% of sales (FY25: 42.2%) • Improved margins in core businesses Gross margin in line at 42.5% (FY25: 42.2%) through pricing and procurement discipline • Prioritised c
Slide 5: Executive Summary: FY26 Highlights
Executive Summary FY26 Highlights For personal use only • Statutory profit after tax of $34,728 (FY25: $3,981,298) • Group EBITDA positive at $0.14m (FY25: $3k); Adjusted EBITDA of $0.27m, up 49% • Group revenue steady at $10.27m as Cardio growth offset the ambIT infusion pump transition • Cardio re
Slide 6: Key Message for Investors
Key Message for Investors What Matters This Year For personal use only • The first-half loss reversed – H2 delivered EBITDA of $0.24m and a statutory profit • Earnings quality improved: margin up, costs down, cash up • Revenue base rebalanced toward Cardio, reducing reliance on infusion pumps • Flat
Slide 7: Statutory Results - FY26 vs FY25
Statutory Results - FY26 vs FY25 FY26 ($) FY25 ($) For personal use only Interest income 29,419 9,960 Gain on investments 433,135 4,646,820 Total expenses 427,826 675,482 Profit before tax 34,728 3,981,298 Profit for the period 34,728 3,981,298 FY25 included an exceptionally large fair value gain on
Slide 8: BTC Health and investee companies FY26 financial highlights
BTC Health and investee companies FY26 financial highlights Revenue Gross Profit For personal use only $10.3m $4.4m • Group revenue steady at $10.27m (FY25: $10.23m) – 31% Cardio growth offset a 35% decline in infusion pumps following the ambIT discontinuation. Flat on FY25 +1% on FY25 • Corcym hear
Slide 9: FY26 Key Financial Metrics
FY26 Key Financial Metrics Group Sales Gross Profit Gross Margin $ millions $ millions $4.3 $4.4 45% $10.2 $10.3 For personal use only 43% 42% 42% $3.6 40% $8.2 $3.3 $7.7 $7.8 $3.1 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Group Operating Costs Group EBITDA EBITDA of
Slide 10: Revenue by Segment - FY26 vs FY25
Revenue by Segment - FY26 vs FY25 Revenue Split - FY26 Revenue Split - FY25 Pharma 11% Infusion Pumps Pharma 12% 29% For personal use only Infusion Pumps 19% Cardio 57% Neurospinal 13% Neurospinal 15% Cardio 44% Cardio now represents 57% of Group revenue (FY25: 44%), driven by a full year of Corcym
Slide 11: From First-Half Loss to Full-Year Positive EBITDA
From First-Half Loss to Full-Year Positive EBITDA What changed in the second half For personal use only • Purchase order timing normalised Orders deferred out of H1 converted in H2, lifting second-half revenue to $5.29m • Cardio scaled A full year of Corcym heart valves plus first-year cannula reven
Slide 12: Key Operational Milestones in FY26
Operational Achievements Key Operational Milestones in FY26 For personal use only • Full-year integration of the Corcym heart valve business – revenue up 91% to $2.34m • Cardiopulmonary bypass cannulas introduced, contributing $0.73m in their first year • PEARS aortic root support implants grew 20%
Slide 13: Capital Raising & Shareholder Support
Capital Raising & Shareholder Support Capital Raising Strengthens Balance Sheet & Investor Base For personal use only • Completed a $1.96m share placement to professional and sophisticated investors in December 2025 • Strong demand from both existing and new institutional / sophisticated investors •
Slide 14: Product Portfolio Strength
Product Portfolio Strength Diversification of the Core Business • Broad range of medical devices, consumables and specialty pharmaceuticals For personal use only • Exposure across cardiac, critical care, neuro-spinal, pain management and respiratory • No single product line represents more than a qu
Slide 15: Growth Strategy: FY27 Strategic Priorities
Growth Strategy FY27 Strategic Priorities For personal use only • Grow Cardio further – additional ECMO tenders and increased Perceval Plus valve utilisation • Convert remaining infusion pump users across to Elasto-Q and Micrel • Expand the customer base for the neuro-spinal product range • Add new
Slide 16: Improving Australian lives through global medical innovation
Improving Australian lives through global medical innovation For personal use only For more information, please contact: BTC Health Limited Dr Richard Treagus Salesh Balak Executive Chairman Chief Financial Officer +61 417 520 509 +61 414 508 852 rtreagus@btchealth.com.au sbalak@btchealth.com.au 16